Table 1 Baseline characteristics and treatment regimen of included studies
Study | Time | Location | Population | Trial Group | Control Group | Study duration (wk) | Main outcome | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
n | Age(y) | Treatment regimen | n | Age(y) | Treatment regimen | ||||||
Himanshu | 2019 | USA | fibromyalgia | 91 | 15.74 + 1.4 | Duloxetine 30-60 mg/d | 93 | 15.33 + 1.4 | placebo | 13 | ①②⑤⑦ |
Uchio | 2018 | Japan | KOA | 177 | 65.5 ± 8.0 | Duloxetine 60 mg/d | 176 | 66.4 ± 8.4 | placebo | 14 | ①②③④⑤⑥⑦ |
Wang | 2017 | China | KOA/Hip | 205 | 61.2 ± 8.2 | Duloxetine 60 mg/d | 202 | 59.8 ± 8.4 | placebo | 13 | ①②③⑤⑥⑦ |
Murakami | 2015 | Japan | fibromyalgia | 191 | 47.8 ± 12.0 | Duloxetine 60 mg/d | 195 | 49.5 ± 11.7 | placebo | 14 | ①②④⑤⑥⑦ |
Abou-Raya | 2012 | Egypt | KOA | 144 | 68.9 ± 6.2 | Duloxetine 60 mg/d | 144 | 68.5 ± 5.8 | placebo | 16 | ③ |
Arnold | 2012 | USA | fibromyalgia | 155 | 50.9 ± 11.9 | Duloxetine 30 mg/d | 153 | 50.7 ± 12.5 | placebo | 12 | ①④⑤⑥⑦ |
Frakes | 2011 | USA | KOA | 264 | 61.6 ± 9.2 | Duloxetine 60-120 mg/d + NSAIDs | 260 | 60.3 ± 9.2 | placebo + NSAIDs | 10 | ①②③⑤⑥⑦ |
Chappell | 2011 | USA | KOA | 128 | 63.2 ± 8.8 | Duloxetine 60-120 mg/d | 128 | 61.9 ± 9.2 | placebo | 13 | ①②③④⑤⑥⑦ |
Arnold | 2010 | USA | fibromyalgia | 263 | 50.7 ± 11.3 | Duloxetine 60-120 mg/d | 267 | 49.6 + 10.8 | placebo | 24 | ①④⑤⑦ |
Chappell | 2009 | USA | KOA | 111 | 62.1 ± 9.6 | Duloxetine 60-120 mg/d | 120 | 62.5 ± 9.3 | placebo | 13 | ①②③④⑤⑥⑦ |
Russell | 2008 | USA | fibromyalgia | 147 | 51.5 ± 10.8 | Duloxetine 120 mg/d | 144 | 50.3 ± 10.9 | placebo | 24 | ①④⑤⑥ |
Arnold | 2005 | USA | fibromyalgia | 116 | 49.6 ± 10.9 | Duloxetine 120 mg/d | 120 | 49.6 ± 10.9 | placebo | 12 | ①②④⑤⑥⑦ |
Arnold | 2004 | USA | fibromyalgia | 104 | 49.9 ± 12.3 | Duloxetine 120 mg/d | 103 | 48.3 ± 11.3 | placebo | 12 | ①④⑤⑥ |